Coherus Oncology, Inc.
CHRS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 3.8% | 21.9% | -35.4% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 56% | 38.2% | 66.8% | 82.4% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $1 |
| Operating Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -41.8% | -79% | -121.7% | -80.8% |
| Other Income/Exp. Net | $0 | -$0 | -$0 | -$0 |
| Pre-Tax Income | $0 | -$0 | -$0 | -$0 |
| Tax Expense | $0 | -$0 | $0 | $0 |
| Net Income | $0 | -$0 | -$0 | -$0 |
| % Margin | 10.7% | -92.5% | -138.2% | -87.9% |
| EPS | 0.25 | -2.53 | -3.76 | -3.81 |
| % Growth | 109.9% | 32.7% | 1.3% | – |
| EPS Diluted | 0.25 | -2.53 | -3.76 | -3.81 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $0 | -$0 | -$0 | -$0 |
| % Margin | 22.8% | -75.4% | -121.1% | -79.8% |